Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

@article{Cheung2016TargetingAE,
  title={Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia},
  author={N. Cheung and T. Fung and B. B. Zeisig and K. Holmes and J. Rane and K. Mowen and M. G. Finn and B. Lenhard and L. Chan and C. So},
  journal={Cancer Cell},
  year={2016},
  volume={29},
  pages={32 - 48}
}
Summary Transcriptional deregulation plays a major role in acute myeloid leukemia, and therefore identification of epigenetic modifying enzymes essential for the maintenance of oncogenic transcription programs holds the key to better understanding of the biology and designing effective therapeutic strategies for the disease. Here we provide experimental evidence for the functional involvement and therapeutic potential of targeting PRMT1, an H4R3 methyltransferase, in various MLL and non-MLL… Expand
The PAF Complex Regulation of Prmt5 Facilitates the Progression and Maintenance of MLL-Fusion Leukemia
TLDR
Overall, it is demonstrated the PAFc regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for AMLs. Expand
PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma
TLDR
It is shown that PRMT2 is highly expressed in Glioblastoma multiforme (GBM) and evidence is provided thatPRMT2 acts as a transcriptional co-activator for oncogenic gene expression programs, at least partly dependent on its H3R8me2a activity, in GBM pathogenesis. Expand
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML
TLDR
It is shown that genetic inactivation or small-molecule inhibition of the protein arginine methyltransferase PRMT5 exhibit anti-tumoral activity in MLL-fusion protein-driven transformation. Expand
Novel therapeutic strategies for MLL-rearranged leukemias.
TLDR
Some of the recent advances in the development of epigenetic and DDR therapeutics by targeting epigenetic regulators or protein complexes that mediate MLL-r leukemia gene expression program and key players in DDR that safeguard essential genome integrity are summarized. Expand
Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
TLDR
This review will consider the role of two cellular processes, metabolism and epigenetics, in the development and progression of AML and highlight the studies that suggest an interconnection of therapeutic importance between the two. Expand
Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.
TLDR
Results indicate that abolishing FLT3 arginine methylation through PRMT1 inhibition represents a promising strategy to target MLL-r ALL cells. Expand
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.
TLDR
It is shown that knockout of Carm1 abrogates both the initiation and maintenance of acute myeloid leukemia (AML) driven by oncogenic transcription factors, and suggests that targeting CARM1 may be an effective therapeutic strategy for AML. Expand
KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
TLDR
Examination of expression of histone-3-lysine (H3K) demethylases and their cognate substrates in a cohort of de novo AML patients demonstrated that the expression of H3K27Me3/2-dem methylases and selected members of H 3K9Me 3/2/1-demethylases are significantly increased in AML. Expand
Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
TLDR
Recent advances in development of small-molecule inhibitors specific to chromatin factors and their potential applications in the treatment of genetically defined AMLs are summarized. Expand
Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis.
TLDR
It is shown that expression of m6A demethylase ALKBH5 is regulated by chromatin state alteration during leukemogenesis of human acute myeloid leukemia (AML), and ALKBh5 is required for maintaining leukemia stem cell (LSC) function but is dispensable for normal hematopoiesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
TLDR
The results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention. Expand
The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
TLDR
It is reported that LSCs in MLL-associated leukemia reside in an epigenetic state of relative genome-wide high-level H3K4me3 and low-levelH3K79me2, and a crucial role for the H 3K4 global methylome in determining LSC fate is demonstrated. Expand
hDOT1L Links Histone Methylation to Leukemogenesis
TLDR
It is reported that hDOT1L interacts with AF10, an MLL (mixed lineage leukemia) fusion partner involved in acute myeloid leukemia, through the OM-LZ region of AF10 required for MLL-AF10-mediated leukemogenesis, and suggests that the enzymatic activity of hDot1L may provide a potential target for therapeutic intervention. Expand
Protein arginine-methyltransferase-dependent oncogenesis
TLDR
It is shown that PRMT1 is an essential component of a novel Mixed Lineage Leukaemia (MLL) oncogenic transcriptional complex with both histone acetylation and H4R3 methylation activities, which also correlate with the expression of critical MLL downstream targets. Expand
PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.
TLDR
The discovery of a novel AE9a binding partner PRMT1 (protein arginine methyltransferase 1) is reported, suggesting a potential role ofPRMT1 in regulating leukemia development. Expand
shRNA screening identifies JMJD1C as being required for leukemia maintenance.
TLDR
In both mouse and human leukemic cells, the growth defect upon JM JD1C depletion appears to be primarily due to increased apoptosis, which implicates JMJD1C as a potential therapeutic target in leukemia. Expand
Cooperative epigenetic modulation by cancer amplicon genes.
TLDR
JAK2 and JMJD2C cooperatively remodel the PMBL and HL epigenome, offering a mechanistic rationale for the development of JAK2-mediated histone phosphorylation and JM JD2C inhibitors in these diseases. Expand
The role of mutations in epigenetic regulators in myeloid malignancies
TLDR
Recent genetic and functional data implicating mutations in epigenetic modifiers, including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A) are discussed. Expand
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
TLDR
GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated. Expand
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
TLDR
It is demonstrated that ectopic expression of KDM2b/Jhdm1b is sufficient to transform hematopoietic progenitors and suggests that Kdm2b / Jhdm 1b functions as an oncogene and plays a critical role in leukemia development and maintenance. Expand
...
1
2
3
4
5
...